Drugs / mRNA-1653
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04144348 | Nov 2019 → Dec 2022 | viral respiratory tract infection | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03392389 | Dec 2017 → Jul 2019 | viral respiratory tract infection | ModernaTX, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-10-02 | ModernaTX, Inc. | Results Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019 q4web.com ↗
Phase 1 data show first combination vaccine against respiratory viruses hMPV and PIV3 (mRNA-1653) boosted hMPV and PIV3 neutralizing antibody titers above baseline through seven months; |
| 2019-08-07 | ModernaTX, Inc. | Results Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results q4web.com ↗
Second planned interim analysis of Phase 1 hMPV and PIV3 vaccine (mRNA-1653) study showed antibody titers remained above baseline at all dose levels at seven months |
| 2019-02-12 | ModernaTX, Inc. | Results Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 q4web.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-10-02 | ModernaTX, Inc. | Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019 q4web.com ↗ |
| 2019-08-07 | ModernaTX, Inc. | Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results q4web.com ↗ |
| 2019-02-12 | ModernaTX, Inc. | Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1653 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144348 ↗ |
| Modality | Vaccine | “a combined human metapneumovirus and human parainfluenza virus type 3 vaccine” NCT03392389 ↗ |
| Route | Intramuscular | “administered via intramuscular injection” NCT04144348 ↗ |